Cargando…

Burden of early, advanced and metastatic breast cancer in The Netherlands

BACKGROUND: The aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands. METHODS: Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and were used to calculate the economic and health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vondeling, G. T., Menezes, G. L., Dvortsin, E. P., Jansman, F. G. A., Konings, I. R., Postma, M. J., Rozenbaum, M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842550/ https://www.ncbi.nlm.nih.gov/pubmed/29514651 http://dx.doi.org/10.1186/s12885-018-4158-3

Ejemplares similares

The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review
por: Vondeling, Gerard T., et al.
Publicado: (2018)

Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
por: Stevanović, J., et al.
Publicado: (2016)

Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity Lost
por: Zeevat, Florian, et al.
Publicado: (2021)

Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer
por: Dvortsin, Evgeni, et al.
Publicado: (2016)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review
por: van Schoonhoven, Alexander V., et al.
Publicado: (2019)

Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study
por: Mansfield, Carol, et al.
Publicado: (2022)

Real-world data of HER2-low metastatic breast cancer: A population based cohort study
por: Holthuis, Emily I., et al.
Publicado: (2022)

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
por: Rozenbaum, Mark H, et al.
Publicado: (2011)

The impact of patent expiry on drug prices: insights from the Dutch market
por: van der Schans, Simon, et al.
Publicado: (2020)

Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data
por: van Leent, Merlijn W. J., et al.
Publicado: (2015)

An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”
por: Tu, Hong Anh T, et al.
Publicado: (2013)

Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands
por: Pierik, Jorien GJ, et al.
Publicado: (2012)

1439. The Cost-Effectiveness of Vaccinating Adults at Increased Risk of Pneumococcal Disease Against Pneumococcal Disease in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?
por: Urbanus, Anouk T., et al.
Publicado: (2013)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

Decreased rates of advanced breast cancer due to mammography screening in The Netherlands
por: Fracheboud, J, et al.
Publicado: (2004)

Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
por: Dunton, Kyle, et al.
Publicado: (2022)

Burden of serious fungal infections in the Netherlands
por: Buil, Jochem B., et al.
Publicado: (2020)

Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands
por: Schneider, Paul P., et al.
Publicado: (2020)

Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination
por: Assink, M.D.M., et al.
Publicado: (2009)

Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands
por: de Blok, Christel J M, et al.
Publicado: (2019)

Breast cancer risk among first-generation migrants in the Netherlands
por: Visser, O, et al.
Publicado: (2004)

Diagnostics in Patients Suspect for Breast Cancer in The Netherlands
por: Voets, Madelon M., et al.
Publicado: (2021)

Burden of genetic risk variants in multiple sclerosis families in the Netherlands
por: Mescheriakova, Julia Y, et al.
Publicado: (2016)

1434. Cost-Effectiveness of Sequencial Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23 Valent Polysaccharide Vaccine (PPV23) in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Locoregional tumor burden and risk of mortality in metastatic breast cancer
por: Yang, Sherry X., et al.
Publicado: (2022)

Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands
por: Haj Mohammad, N., et al.
Publicado: (2016)

The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke
por: van Eeden, M, et al.
Publicado: (2015)

Impact of medicine shortages on patients - a framework and application in the Netherlands
por: Postma, Doerine J., et al.
Publicado: (2022)

Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA
por: Ragusi, M. A. A., et al.
Publicado: (2022)

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
por: Kwakman, Johannes J. M., et al.
Publicado: (2017)

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
por: Miglietta, F., et al.
Publicado: (2022)

Dutch DALYs, current and future burden of disease in the Netherlands
por: Hilderink, Henk B. M., et al.
Publicado: (2020)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
por: Mulder, Frederike E. C. M., et al.
Publicado: (2021)

The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors
por: van Gemert, W. A., et al.
Publicado: (2015)

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
por: Lobbezoo, D J A, et al.
Publicado: (2015)

Notes on the Particulate Matter Standards in the European Union and the Netherlands
por: Priemus, Hugo, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9ba4l7ta8ii0ci9oq7lh4ln92j